文献速递肺外科

国家肺癌筛查试验中完全切除后非小细胞肺癌的复发情况

Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial.
PubMed 文献 · Ann Thorac Surg · 2023-06-24

该研究基于国家肺癌筛查试验(NLST)评估了完全切除的早期非小细胞肺癌(NSCLC)的复发模式、预测因素和长期结局。497例病理I-II期接受完全切除的患者中,94例复发,5年累积复发率为20.1%。多数复发为远处转移,且与生存期差相关。

要点

  • 完全切除的病理I-II期NSCLC患者5年累积复发率为20.1%(95%CI 16.5%-23.9%)。
  • 复发多位于远处(50.0%)或同时存在局部和远处(31.9%)。
  • 低剂量CT筛查发现的肺癌复发率显著低于胸片筛查或未被筛查发现的肺癌(P < .001)。

核心结论

  • 在NLST参与者中,完全切除的I-II期NSCLC的5年累积复发率为20%。
  • 近82%的复发位于远处,且与生存期差相关。

研究设计与样本

  • 利用国家肺癌筛查试验(NLST)数据,评估病理I-II期接受完全切除(肺叶切除或双肺叶切除)的NSCLC患者的复发频率。
  • 采用Fine-Gray竞争风险回归评估复发风险增加的预测因素。
  • 共纳入497例符合研究标准的患者。

主要发现

  • 497例患者中94例复发,复发率为4.9(95%CI 4.0-6.0)/100人年。
  • 5年累积复发率为20.1%(95%CI 16.5%-23.9%)。
  • 复发部位:单纯远处转移47例(50.0%),局部和远处同时转移30例(31.9%)。
  • 从切除到复发的中位时间为18.8(10.6-30.7)个月。
  • 低剂量CT筛查(NLST三轮筛查之一)发现的肺癌复发率显著低于胸片筛查发现的肺癌及未被任何形式筛查发现的肺癌(P < .001)。

关键数值与推荐

  • 病理I期复发患者中位生存期(自复发日期起):局部复发63.0个月,远处复发23.1个月,局部和远处同时复发9.8个月。
  • 病理II期复发患者中位生存期(自复发日期起):局部复发28.9个月,远处复发8.7个月,局部和远处同时复发10.2个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to evaluate patterns, predictors, and long-term outcomes of recurrent disease after complete resection for early-stage non-small cell lung cancer (NSCLC) using the National Lung Screening Trial (NLST). METHODS: The frequency of recurrence in patients with pathologic stage I-II NSCLC who underwent complete resection (lobectomy or bilobectomy) in the NLST was evaluated. Predictors of increased risk of recurrence were assessed by Fine-Gray competing risks regression. RESULTS: Of the 497 patients meeting study inclusion criteria, 94 experienced a recurrence-a rate of 4.9 (95% CI, 4.0-6.0) per 100 person-years. The 5-year cumulative incidence of recurrence was 20.1% (95% CI, 16.5%-23.9%). Most patients experienced recurrences at distant sites alone (n = 47 [50.0%]) or at both locoregional and distant sites (n = 30 [31.9%]). The median time from resection to recurrence was 18.8 (10.6-30.7) months. The incidence rate of recurrence was significantly lower among patients with lung cancer detected by low-dose computed tomography screening during one of the three screening rounds of the NLST when compared with patients with lung cancer detected by chest radiography screening and patients with lung cancer not detected by any form of screening (ie, those diagnosed after a negative or missed screening exam and those diagnosed during follow-up after the three screening rounds of the NLST were completed) (P < .001). Median survival (from the date of recurrence) of patients with pathologic stage I and stage II disease who had recurrences at locoregional, distant, or both sites was 63.0, 23.1, and 9.8 months and 28.9, 8.7, and 10.2 months, respectively. CONCLUSIONS: In this analysis of NLST participants with completely resected stage I-II NSCLC, the 5-year cumulative incidence of recurrence was 20%. Nearly 82% of recurrences were at distant sites and associated with poor survival.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Potter AL, Costantino CL, Suliman RA, et al. Recurrence After Complete Resection for Non-Small Cell Lung Cancer in the National Lung Screening Trial. Ann Thorac Surg. 2023. PMID: 37356517. doi:10.1016/j.athoracsur.2023.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。